Table 2. Univariate and multivariate analysis for overall survival and progression free survival.
| Factors | Overall survival | Progression–free survival | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate HR, 95% CI | P value | Multivariate HR, 95% CI | P value | Univariate HR, 95% CI | P value | Multivariate HR, 95% CI | P value | ||
| Gender (male vs. female) | 1.788 (0.941–3.4) | 0.076 | 1.836 (0.966–3.489) | 0.064 | |||||
| Age (≥65 vs.<65) | 1.248 (0.713–2.184) | 0.438 | 1.278 (0.73–2.235) | 0.39 | |||||
| No. of metastatic sites (>2 vs.≤2) | 1.442 (0.837–2.483) | 0.187 | 1.52 (0.883–2.619) | 0.131 | |||||
| Smoking history (yes vs. no) | 1.98 (1.16–3.381) | 0.012 | 1.713 (0.986–2.975) | 0.056 | 2.055 (1.203–3.509) | 0.008 | 1.774 (1.027–3.062) | 0.04 | |
| Drinking history (yes vs. no) | 1.6 (0.929–2.755) | 0.09 | 1.721 (0.998–2.968) | 0.051 | |||||
| Lactate dehydrogenase (≥245 vs. <245) | 1.564 (0.894–2.735) | 0.117 | 1.56 (0.89–2.736) | 0.121 | |||||
| Number of previous therapies (1,2 vs. ≥3) | 1.82 (0.961–3.448) | 0.066 | 1.501 (0.8–2.815) | 0.206 | |||||
| Type of inhibitor (Keytruda, Opdivo vs. other) | 1.576 (0.848–2.929) | 0.165 | 1.538 (0.822–2.876) | 0.192 | |||||
| ECOG PS (≥2 vs. 0,1) | 3.865 (2.237–6.677) | <0.001 | 2.36 (1.326–4.202) | 0.004 | 4.187 (2.403–7.294) | <0.001 | 2.862 (1.597–5.128) | <0.001 | |
| LMR-6 week (≤4.15 vs. >4.15) | 4.705 (2.572–8.607) | <0.001 | 3.851 (2.039–7.276) | <0.001 | 3.373 (1.873–6.073) | <0.001 | 2.67 (1.447–4.927) | 0.002 | |
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; No., number; PD-1, programmed death-1; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.